Previously, we reported that targeting SDC1 using the human recombinant antibody scFv (single chain Fragment variable) OC-46F2 was able to inhibit tumor growth in melanoma and human ovarian carcinoma models induced in NOD SCID (Non-Obese Diabetic Severe Combined Immunodeficiency) mice [36]. Here, SDC1 is linked to ovarian carcinoma.